• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.与多发性硬化症疾病改善治疗依从性和持续性相关的因素:一项范围综述文献。
Int J MS Care. 2023 Sep-Oct;25(5):188-195. doi: 10.7224/1537-2073.2021-139. Epub 2023 Sep 14.
2
Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis.真实世界中多发性硬化症患者使用奥法妥木单抗与口服和注射用疾病修正治疗药物的持续性和依从性。
Mult Scler Relat Disord. 2024 Nov;91:105888. doi: 10.1016/j.msard.2024.105888. Epub 2024 Sep 12.
3
Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.客观评估多发性硬化症患者的药物依从性和持续性:系统评价、荟萃分析和荟萃回归。
J Manag Care Spec Pharm. 2021 Sep;27(9):1273-1295. doi: 10.18553/jmcp.2021.27.9.1273.
4
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.多发性硬化症患者二线疾病修正治疗起始治疗模式。
Adv Ther. 2020 Jul;37(7):3163-3177. doi: 10.1007/s12325-020-01367-1. Epub 2020 May 20.
5
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.在美国商业索赔数据中,与其他多发性硬化症的疾病修正疗法相比,奥瑞珠单抗的持续使用和坚持使用。
J Manag Care Spec Pharm. 2021 May;27(5):639-649. doi: 10.18553/jmcp.2021.20413. Epub 2021 Feb 24.
6
Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.评估初治多发性硬化症患者疾病修正治疗的治疗模式、复发情况、医疗资源利用及成本。
Clinicoecon Outcomes Res. 2021 Jan 22;13:65-75. doi: 10.2147/CEOR.S288296. eCollection 2021.
7
Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.对开始二线疾病修正治疗的多发性硬化症患者的治疗模式、复发、医疗资源利用及成本的回顾性索赔分析
Drugs Real World Outcomes. 2021 Dec;8(4):497-508. doi: 10.1007/s40801-021-00251-w. Epub 2021 Jun 16.
8
Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.真实世界中多发性硬化症患者口服疾病修正治疗的 1 年用药依从性和持久性。
J Manag Care Spec Pharm. 2017 Aug;23(8):844-852. doi: 10.18553/jmcp.2017.23.8.844.
9
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.从回顾性理赔分析看新确诊多发性硬化症患者的治疗模式和复发情况。
Clin Ther. 2020 Nov;42(11):2136-2147.e3. doi: 10.1016/j.clinthera.2020.09.014. Epub 2020 Nov 5.
10
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.与其他用于治疗多发性硬化症的疾病修正疗法相比,奥瑞珠单抗相关的工作生产力结果。
Neurol Ther. 2021 Jun;10(1):183-196. doi: 10.1007/s40120-020-00224-1. Epub 2020 Nov 26.

引用本文的文献

1
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States.中断疾病修正疗法对美国中年多发性硬化症患者医疗保健利用的影响。
J Manag Care Spec Pharm. 2024 Nov;30(11):1248-1260. doi: 10.18553/jmcp.2024.30.11.1248.
2
Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis.偏好、依从性和满意度:多发性硬化症患者三年的治疗经历
Patient Prefer Adherence. 2024 Feb 22;18:455-466. doi: 10.2147/PPA.S452849. eCollection 2024.

本文引用的文献

1
Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis.真实世界中多发性硬化症患者对每日一次和每日两次口服疾病修正药物的依从性和持久性:系统评价和荟萃分析。
BMC Neurol. 2020 Jul 14;20(1):281. doi: 10.1186/s12883-020-01830-0.
2
Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis.多模态方法评估多发性硬化症患者在不同时间点对药物的依从性。
Mult Scler Relat Disord. 2020 May;40:101951. doi: 10.1016/j.msard.2020.101951. Epub 2020 Jan 15.
3
Incorporating Clinical Practice Guidelines and Quality Measures Into High-Quality Cost-Effective Care for Patients With Multiple Sclerosis.将临床实践指南和质量指标纳入多发性硬化症患者的高质量、成本效益高的护理中。
Continuum (Minneap Minn). 2019 Jun;25(3):845-849. doi: 10.1212/CON.0000000000000726.
4
Medication adherence among patients with chronic diseases: a survey-based study in pharmacies.慢性病患者的药物依从性:基于药店的调查研究。
QJM. 2019 Jul 1;112(7):505-512. doi: 10.1093/qjmed/hcz058.
5
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.多发性硬化症新型口服疾病修正疗法的坚持和依从性:一项基于人群的研究。
Mult Scler Relat Disord. 2019 Jan;27:364-369. doi: 10.1016/j.msard.2018.11.004. Epub 2018 Nov 9.
6
Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach.系统评价或范围综述?在选择系统评价或范围综述方法时,作者的指南。
BMC Med Res Methodol. 2018 Nov 19;18(1):143. doi: 10.1186/s12874-018-0611-x.
7
Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis.疾病修正治疗(DMT)的费用分担作为改善多发性硬化症 DMT 获得的政策杠杆。
Value Health. 2018 Sep;21(9):1083-1089. doi: 10.1016/j.jval.2017.10.025. Epub 2018 Jan 8.
8
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.PRISMA 扩展用于范围审查 (PRISMA-ScR): 清单和解释。
Ann Intern Med. 2018 Oct 2;169(7):467-473. doi: 10.7326/M18-0850. Epub 2018 Sep 4.
9
A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries.比较医疗保险处方药受益人与专科药物使用和依从性的配药渠道。
J Manag Care Spec Pharm. 2018 Apr;24(4):317-326. doi: 10.18553/jmcp.2018.24.4.317.
10
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.新多发性硬化症时代治疗持久性的多中心观察性分析:RESPECT 研究。
J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

与多发性硬化症疾病改善治疗依从性和持续性相关的因素:一项范围综述文献。

Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.

作者信息

Ben-Zacharia Aliza Bitton, Walker Bryan, Ross Amy Perrin, Tornatore Carlo, Edwards Natalie C, Lipman Yvette, Phillips Amy L

机构信息

From Bellevue School of Nursing, Hunter College, New York, NY, USA (AB-Z).

Mount Sinai Medical Center, New York, NY, USA (AB-Z).

出版信息

Int J MS Care. 2023 Sep-Oct;25(5):188-195. doi: 10.7224/1537-2073.2021-139. Epub 2023 Sep 14.

DOI:10.7224/1537-2073.2021-139
PMID:37720259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10503813/
Abstract

BACKGROUND

Patients with multiple sclerosis (MS) receiving disease-modifying therapies (DMT) show published adherence rates of 27.0% to 93.8% and published persistence rates of 49.7% to 96.5%. Improvements in DMT adherence and persistence are key to optimizing MS care, and enhanced understanding could improve MS disease management and identify research gaps. This scoping literature review aims to examine the nature and findings of the literature evaluating factors associated with DMT adherence and persistence in patients with MS.

METHODS

Eligible articles included in the literature review were quantitative clinical studies written in English, included adherence or persistence as primary outcomes, and accounted for covariates/confounders. The articles were assessed to identify factors associated with adherence/persistence and analyzed according to DMT type (self-injectable, oral, infusion).

RESULTS

Fifty-eight studies (103,450 patients) were included. Study distribution by DMT type was self-injectable only (n = 41), oral only (n = 2), infusion only (n = 1), and more than 1 type (n = 14). Older age and previous DMT use were associated with increased adherence and/or persistence. Increased alcohol consumption, DMT adverse events, higher education, and higher body mass index were negatively associated with adherence and/or persistence. Greater number and severity of relapses was associated with increased adherence but decreased persistence.

CONCLUSIONS

Most studies examined factors associated with adherence and persistence to self-injectable DMTs. These factors should be evaluated further for oral and infusion DMTs. Insights into the modifiable factors associated with adherence and persistence could guide treatment decisions and help improve adherence and clinical outcomes.

摘要

背景

接受疾病修正治疗(DMT)的多发性硬化症(MS)患者公布的依从率为27.0%至93.8%,持续率为49.7%至96.5%。提高DMT的依从性和持续率是优化MS护理的关键,深入了解可能会改善MS疾病管理并发现研究空白。本范围文献综述旨在研究评估与MS患者DMT依从性和持续率相关因素的文献的性质和研究结果。

方法

纳入文献综述的合格文章为用英文撰写的定量临床研究,将依从性或持续率作为主要结局,并考虑了协变量/混杂因素。对文章进行评估以确定与依从性/持续率相关的因素,并根据DMT类型(自我注射、口服、输液)进行分析。

结果

纳入了58项研究(103450名患者)。按DMT类型的研究分布为仅自我注射(n = 41)、仅口服(n = 2)、仅输液(n = 1)以及不止一种类型(n = 14)。年龄较大和既往使用DMT与依从性和/或持续率增加相关。饮酒量增加、DMT不良事件、高等教育程度和较高的体重指数与依从性和/或持续率呈负相关。复发次数和严重程度增加与依从性增加但持续率降低相关。

结论

大多数研究考察了与自我注射DMT依从性和持续率相关的因素。对于口服和输液DMT,应进一步评估这些因素。对与依从性和持续率相关的可改变因素的深入了解可为治疗决策提供指导,并有助于提高依从性和临床结局。